Short answer
Beta Bionics, Inc. (BBNX) filed its Q1 2026 10-Q quarterly report on Apr 21, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $28M (up 56.6% year over year) with net income of −$22M.
Q1 2026 key financials · XBRL
- Revenue
- $28M
- +56.6% YoY
- Net income
- −$22M
- +23.6% YoY
- Operating margin
- -87.9%
- Gross margin
- 59.5%
- EPS (diluted)
- −$0.49
- +47.3% YoY
Source: XBRL data from the Beta Bionics, Inc. (BBNX) Q1 2026 10-Q on SEC EDGAR. USD.
Beta Bionics, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue figures and YoY change not provided in supplied MD&A
- PBP sales 39% of net sales vs 22% YoY
- MDI users represented 70% of adoption vs 71% YoY
- Cash position, operating cash flow, and capital deployment figures not provided
- FDA Warning Letter, increased R&D investment, and reimbursement-channel mix headwinds
Risk Factors
- No Risk Factors section provided; supplied text begins with Item 2
- No newly added risk factor or 10-K comparison disclosed
- Rule 10b5-1 plans adopted to sell 17,155 shares through December 31, 2026
- No regulatory, legal, operational, competitive, market, or financial risks described
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Beta Bionics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.